MDGL Target Price: 88% Confidence
MDGL has been forming a bullish Head-and-Shoulders Bottom pattern since February 28, 2023. This pattern is a reliable bullish indicator and occurs when a stock's price falls to a low, bounces back up, forms a lower low, bounces back up again to form a higher low, and then breaks above the resistance level formed by the neckline of the pattern. This pattern signals that the stock is likely to experience a bullish move in the near future.
The Head-and-Shoulders Bottom pattern for MDGL was confirmed on April 24, 2023, when the stock broke above the neckline of the pattern. This confirmed the bullish signal and suggested that the stock could be headed higher in the coming weeks.
Currently, there is a high confidence level of 88% that MDGL will reach the target price of 358.47 USD. The distance to the target price is 17%, which means that there is still some room for the stock to move higher. The breakout (entry) price is 306.92 USD, which can be used as a reference point for traders to enter the stock.
Adding to the bullish sentiment is the recent trigger of the Aroon Indicator. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. This is a sign that the stock is setting up for a bullish move. In fact, A.I.dvisor looked at 147 similar instances where the Aroon Indicator showed a similar pattern, and in 127 of those cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
In conclusion, MDGL's Head-and-Shoulders Bottom pattern and the recent trigger of the Aroon Indicator suggest that the stock is likely to experience a bullish move in the coming weeks. With a high confidence level of 88% and the distance to the target price at 17%, there is still room for the stock to move higher. Traders may want to consider buying the stock or look to buy call options to take advantage of the potential upside.
MDGL's RSI Indicator recovers from oversold territory
The RSI Indicator for MDGL moved out of oversold territory on February 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 32 similar instances when the indicator left oversold territory. In of the 32 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on March 13, 2026. You may want to consider a long position or call options on MDGL as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MDGL just turned positive on March 05, 2026. Looking at past instances where MDGL's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in of 289 cases, the price rose further within the following month. The odds of a continued upward trend are .
MDGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MDGL entered a downward trend on March 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.920) is normal, around the industry mean (29.967). P/E Ratio (0.000) is within average values for comparable stocks, (40.439). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.795). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (10.417) is also within normal values, averaging (309.856).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases
Industry Biotechnology
Advertisement